Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.2
(7.22%)
TWD 28.2
(7.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 757.3 Million TWD | -25.3% |
| 2022 | 961.75 Million TWD | 1.3% |
| 2021 | 949.38 Million TWD | 38.24% |
| 2020 | 686.75 Million TWD | 46.55% |
| 2019 | 468.62 Million TWD | 33.32% |
| 2018 | 351.51 Million TWD | -13.82% |
| 2017 | 407.86 Million TWD | -1.59% |
| 2016 | 414.46 Million TWD | 1.97% |
| 2015 | 406.47 Million TWD | 36.97% |
| 2014 | 296.75 Million TWD | -20.86% |
| 2013 | 374.99 Million TWD | -27.93% |
| 2012 | 520.29 Million TWD | 14.73% |
| 2011 | 453.49 Million TWD | 0.36% |
| 2010 | 451.89 Million TWD | -14.49% |
| 2009 | 528.45 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 106.4 Million TWD | -24.21% |
| 2024 Q2 | 107.26 Million TWD | 0.81% |
| 2023 Q1 | 348.7 Million TWD | 52.14% |
| 2023 Q4 | 140.4 Million TWD | 38.13% |
| 2023 Q2 | 156.31 Million TWD | -55.17% |
| 2023 FY | 718.39 Million TWD | -25.3% |
| 2023 Q3 | 101.64 Million TWD | -34.97% |
| 2022 Q1 | 262.62 Million TWD | 4.3% |
| 2022 Q4 | 229.19 Million TWD | 13.2% |
| 2022 Q3 | 202.46 Million TWD | -24.31% |
| 2022 FY | 961.75 Million TWD | 1.3% |
| 2022 Q2 | 267.47 Million TWD | 1.85% |
| 2021 Q2 | 251.17 Million TWD | 17.63% |
| 2021 Q3 | 232.88 Million TWD | -7.28% |
| 2021 FY | 949.38 Million TWD | 38.24% |
| 2021 Q1 | 213.52 Million TWD | -19.12% |
| 2021 Q4 | 251.8 Million TWD | 8.12% |
| 2020 Q4 | 264 Million TWD | 112.67% |
| 2020 Q3 | 124.13 Million TWD | -32.58% |
| 2020 Q1 | 114.48 Million TWD | -14.85% |
| 2020 FY | 686.75 Million TWD | 46.55% |
| 2020 Q2 | 184.12 Million TWD | 60.83% |
| 2019 Q4 | 134.44 Million TWD | 30.15% |
| 2019 FY | 468.62 Million TWD | 33.32% |
| 2019 Q3 | 103.29 Million TWD | 2.23% |
| 2019 Q2 | 101.04 Million TWD | -22.17% |
| 2019 Q1 | 129.83 Million TWD | 36.6% |
| 2018 FY | 351.51 Million TWD | -13.82% |
| 2018 Q3 | 64.26 Million TWD | -38.81% |
| 2018 Q2 | 105.03 Million TWD | 20.5% |
| 2018 Q1 | 87.16 Million TWD | -22.31% |
| 2018 Q4 | 95.05 Million TWD | 47.91% |
| 2017 Q1 | 82.73 Million TWD | -27.47% |
| 2017 Q3 | 149.6 Million TWD | 136.21% |
| 2017 Q2 | 63.33 Million TWD | -23.44% |
| 2017 Q4 | 112.18 Million TWD | -25.01% |
| 2017 FY | 407.86 Million TWD | -1.59% |
| 2016 Q4 | 114.06 Million TWD | 14.77% |
| 2016 Q1 | 105.9 Million TWD | -38.66% |
| 2016 Q3 | 99.38 Million TWD | 4.5% |
| 2016 FY | 414.46 Million TWD | 1.97% |
| 2016 Q2 | 95.1 Million TWD | -10.19% |
| 2015 Q3 | 97.55 Million TWD | 6.4% |
| 2015 FY | 406.47 Million TWD | 36.97% |
| 2015 Q1 | 44.57 Million TWD | -50.07% |
| 2015 Q2 | 91.68 Million TWD | 105.69% |
| 2015 Q4 | 172.65 Million TWD | 76.98% |
| 2014 Q2 | 93.61 Million TWD | 16.32% |
| 2014 Q3 | 33.4 Million TWD | -64.32% |
| 2014 Q1 | 80.47 Million TWD | 16.49% |
| 2014 FY | 296.75 Million TWD | -20.86% |
| 2014 Q4 | 89.26 Million TWD | 167.27% |
| 2013 Q1 | 111.82 Million TWD | 46.56% |
| 2013 FY | 374.99 Million TWD | -27.93% |
| 2013 Q3 | 80.09 Million TWD | -29.73% |
| 2013 Q4 | 69.08 Million TWD | -13.75% |
| 2013 Q2 | 113.98 Million TWD | 1.93% |
| 2012 Q2 | 184.02 Million TWD | 45.63% |
| 2012 FY | 520.29 Million TWD | 14.73% |
| 2012 Q4 | 76.3 Million TWD | -42.86% |
| 2012 Q3 | 133.54 Million TWD | -27.43% |
| 2012 Q1 | 126.36 Million TWD | -11.15% |
| 2011 Q2 | 103.47 Million TWD | 4.72% |
| 2011 Q1 | 98.81 Million TWD | -9.45% |
| 2011 Q3 | 108.97 Million TWD | 5.31% |
| 2011 FY | 453.49 Million TWD | 0.36% |
| 2011 Q4 | 142.22 Million TWD | 30.51% |
| 2010 Q1 | 97.42 Million TWD | 0.0% |
| 2010 FY | 451.89 Million TWD | -14.49% |
| 2010 Q2 | 121.49 Million TWD | 24.71% |
| 2010 Q4 | 109.12 Million TWD | -11.89% |
| 2010 Q3 | 123.84 Million TWD | 1.94% |
| 2009 FY | 528.45 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Apex Biotechnology Corp. | 531.11 Million TWD | -42.588% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.09 Billion TWD | 30.601% |
| Panion & Bf Biotech Inc. | 912.56 Million TWD | 17.013% |
| GenMont Biotech Incorporation | 177.33 Million TWD | -327.047% |
| Abnova (Taiwan) Corporation | 173.91 Million TWD | -335.447% |
| Adimmune Corporation | 410.93 Million TWD | -84.289% |
| Tanvex BioPharma, Inc. | 59.7 Million TWD | -1168.501% |
| Polaris Group | -137.9 Million TWD | 649.168% |
| Energenesis Biomedical CO.,LTD. | 5.22 Million TWD | -14388.387% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -4131.48% |
| PELL Bio-Med Technology Co. Ltd. | -26.14 Million TWD | 2997.123% |